Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex Blepharitis
21 juin 2021 06h00 HE
|
Tarsus Pharmaceuticals, Inc
Saturn-1 Phase 2b/3 trial met all primary and secondary endpoints, and demonstrated significant, clinically meaningful outcomes with no serious treatment-related adverse events and no...
Tarsus Pharmaceuticals, Inc. Schedules Conference Call and Webcast to Announce Saturn-1 Phase 2b/3 Pivotal Trial Results for TP-03 for the Treatment of Demodex Blepharitis
18 juin 2021 16h05 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., June 18, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply...
Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual Healthcare Conference
24 mai 2021 16h05 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply...
Eyenuk Reports Strong 2021 Business Growth
12 mai 2021 11h00 HE
|
Eyenuk, Inc.
LOS ANGELES, May 12, 2021 (GLOBE NEWSWIRE) -- Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye...
Tarsus Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business and Clinical Updates
11 mai 2021 16h05 HE
|
Tarsus Pharmaceuticals, Inc
Initiated Saturn-2, second pivotal Phase 3 trial evaluating the safety and efficacy of TP-03 for the treatment of Demodex blepharitis; topline data from Saturn-1 expected this July Announced FDA...
Von’s Vision Eye Care Appointments Available at Denver Area Adventure Vision Practices for Uninsured Children
10 mai 2021 17h22 HE
|
Adventure Dental, Vision and Orthodontics
COLORADO SPRINGS, Colo., May 10, 2021 (GLOBE NEWSWIRE) -- Hero Practice Services is proud to announce that they are sponsoring several Von’s Locker days at Adventure Vision locations in the...
Tarsus Pharmaceuticals, Inc. Initiates Saturn-2, Second Pivotal Phase 3 Trial Evaluating the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
06 mai 2021 16h05 HE
|
Tarsus Pharmaceuticals, Inc
Demodex blepharitis may affect up to 25 million Americans and result in significant clinical, functional and psychosocial burden for patients Saturn-2 trial design similar to Saturn-1, first pivotal...
Tarsus Pharmaceuticals, Inc. Presents Results of Pioneering Atlas Study at ARVO 2021 Annual Meeting Demonstrating the Functional and Psychosocial Impact of Demodex Blepharitis
03 mai 2021 16h08 HE
|
Tarsus Pharmaceuticals, Inc
Demodex blepharitis is a common ocular condition that may affect up to 25 million Americans Atlas study shows that Demodex blepharitis negatively impacts daily life for 80 percent of patients ...
Outlook on the Dry Eye Disease (DED) Global Market to 2026 - Featuring Johnson & Johnson, Bausch Health and Alcon Among Others
29 avr. 2021 05h13 HE
|
Research and Markets
Dublin, April 29, 2021 (GLOBE NEWSWIRE) -- The "Global Dry Eye Disease (DED) Market - Analysis By Disease (Aqueous, Evaporative, Others), Treatment, End User, Distribution Channel, By Region, By...
Tarsus Pharmaceuticals, Inc. to Present at the BofA Securities 2021 Virtual Health Care Conference
27 avr. 2021 16h05 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply...